Develops a medically approved brain stimulation headset and therapy app for treating depression at home.
About
Flow Neuroscience offers the Flow FL-100, the first and only FDA-approved at-home transcranial direct current stimulation (tDCS) treatment for adults aged 18 and older with moderate to severe Major Depressive Disorder. This neuromodulation treatment can be used as a standalone therapy or as an adjunct to antidepressant medication, with US availability expected in summer 2026. The company highlights its product's favorable safety profile and potential to reduce suicidal ideation and avoid psychiatric hospital admissions.
Tags
Performance
Company Timeline
No timeline data for this period
Score Breakdown
62Traction
37Team
60Visibility
8Profile
0Community
0Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Flow Neuroscience do?
Flow Neuroscience offers the Flow FL-100, the first and only FDA-approved at-home transcranial direct current stimulation (tDCS) treatment for adults aged 18 and older with moderate to severe Major Depressive Disorder. This neuromodulation treatment can be used as a standalone therapy or as an adjunct to antidepressant medication, with US availability expected in summer 2026. The company highlights its product's favorable safety profile and potential to reduce suicidal ideation and avoid psychia…
How much funding has Flow Neuroscience raised?
Flow Neuroscience has raised a total of $22M in funding. The most recent round on record is Series A.
Where is Flow Neuroscience headquartered?
Flow Neuroscience is headquartered in Malmö, Sweden.
When was Flow Neuroscience founded?
Flow Neuroscience was founded in 2016.
What industry does Flow Neuroscience operate in?
Flow Neuroscience operates in HealthTech, MedTech, Digital Therapeutics.